Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EXTI - only public co. developing liver device -- Ignore unavailable to you. Want to Upgrade?

To: William A. Eydler who wrote (161)	1/26/1998 9:06:00 PM
From: MaxLeverage	Read Replies (1) \| Respond to of 1063

Monday January 26, 7:20 pm Eastern Time Company Press Release Xenogenics Corp. Expands Scientific Advisory Board, Appoints James P. Filkins, Ph.D. SAN DIEGO--(BW HealthWire)--Jan. 26, 1998--Dr. Jim Considine, president, Xenogenics Corp., announced Monday that Dr. James P. Filkins has accepted a position on the Scientific Advisory Board of the company. Filkins is professor emeritus of physiology and surgery at Loyola University Stritch School of Medicine in Chicago, where Xenogenics expects to begin bio-artificial liver research in the near future. Considine stated, ''Dr. Filkins' acceptance of a seat on our advisory board is further indication of the scientific community's confidence in our artificial liver technology. As a noted researcher in hepatic TNF production and cellular and molecular physiology, and author of hundreds of articles and abstracts, Jim Filkins will add new depth and dimension to our medical advisory team.'' Filkins is an active member and officer of numerous professional societies, including the American Physiological Society and the Society for Experimental Biology and Medicine. Filkins, a past chairman of the Stritch School of Medicine department of physiology (1975-1992), was previously a tenured associate professor at the University of Tennessee Medical Units, where he began his teaching and research career in 1965 after receiving his doctorate and doing postdoctoral research at Marquette University in 1964. The Sybiol liver support device is intended to be used before and after transplant surgery as an ''artificial liver'' to transplant candidates when no donor organ is available or to assist patients with chronic liver disease or other liver trauma. It is also intended to perform a function for the liver similar to the function renal dialysis performs for kidneys. The proprietary Sybiol device (patent pending) will utilize porcine hepatocytes to provide continuous, sustained removal of human blood toxins outside the liver. Xenogenics Corp. is a 100-percent-owned subsidiary of Exten Industries Inc. (OTC BB:EXTI - news), 9625 Black Mountain Road, Suite 218, San Diego, CA 92126-4564. For information, call Jerry Newmin or Barbara Corbett at 619/578-9784 or e-mail at extixeno@aol.com. Exten's Web site address is exten.com. The matters set forth in this press release are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission, including the company's annual report, quarterly reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements. ------------------------------------------------------------------------ Contact: Xenogenics Corp. Jim Considine, 714/451-1500 or Exten Industries Inc. W. Gerald Newmin or Barbara Corbett, 619/578-9784 After hours: 619/455-7205 or 619/423-3737 biz.yahoo.com